Show simple item record

dc.contributor.authorGarassino, MC
dc.contributor.authorPaz-Ares, L
dc.contributor.authorHui, R
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorSpira, A
dc.contributor.authorPlanchard, D
dc.contributor.authorOzguroglu, M
dc.contributor.authorDaniel, DB
dc.contributor.authorVicente, D
dc.contributor.authorMurakami, S
dc.contributor.authorRyden, A
dc.contributor.authorZhang, Y
dc.contributor.authorO'Brien, C
dc.contributor.authorDennis, PA
dc.contributor.authorAntonia, SJ
dc.date.accessioned2020-03-27T09:27:59Z
dc.date.available2020-03-27T09:27:59Z
dc.date.issued2019en
dc.identifier.citationGarassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, et al. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). Ann Oncol. 2019;30 Suppl 2:ii78.en
dc.identifier.pmid32131355en
dc.identifier.doi10.1093/annonc/mdz094.001en
dc.identifier.urihttp://hdl.handle.net/10541/622822
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz094.001en
dc.titlePatient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThoracic Unit, Fondazione IRMedical Oncology, University Hospital 12 de Octubre, Madrid, Spainen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-03-30T13:21:34Z


Files in this item

Thumbnail
Name:
32131355.pdf
Size:
68.70Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record